Is Sysmex profitable in 2026?

Yes but profit fell sharply. For FY2026 (ended March 2026), Sysmex reported net sales of ¥500.0 billion (-1.7% YoY), operating profit of ¥51.8 billion (-40.8%), and profit attributable to owners of ¥35.4 billion (-33.9%), driven by China policy headwinds and goodwill impairment, per its May 14, 2026 results filing.

Who owns Sysmex Corporation?

Sysmex is an independent public company listed on the Tokyo Stock Exchange Prime Market (ticker 6869), with no parent company. As of April 2026, Hisashi Ietsugu serves as Chairman and Group CEO, and Iwane Matsui as President.

Could AI replace Sysmex's diagnostics business?

Unlikely soon. Sysmex's moat rests on FDA/EMA-cleared hardware, proprietary reagent chemistry, and a closed instrument-reagent ecosystem across 190+ export markets, which pure software cannot replicate. Sysmex itself is adding AI as a feature layer, launching 'Sysmex AI' digital solutions within FY2026 rather than being displaced by it.

Is Sysmex laying off employees?

No signs of layoffs; headcount has grown steadily, reaching 10,533 group employees as of March 31, 2025, up 4.89% year-on-year from 10,042 in March 2024, per Sysmex's own shareholder disclosures.

Who is Sysmex's biggest competitor?

Sysmex competes with Beckman Coulter (Danaher), Abbott Laboratories, and Siemens Healthineers in hematology and clinical diagnostics, while Shenzhen Mindray Bio-Medical Electronics is pushing upmarket with lower-cost analyzers, though no confirmed installed-base losses for Sysmex have been reported as of mid-2026.

Why did Sysmex's stock and profit struggle in 2026?

China's 'principle of minimal necessity' policy curbed diagnostic test volumes, cutting Sysmex's China sales roughly 17.9% year-on-year in H1 FY2026 (local currency), alongside distributor destocking and a goodwill impairment, pushing FY2026 operating profit down 40.8% to ¥51.8 billion.

Biotech tools companies · Japan

Sysmex Corporation

sysmex.com ↗

Sysmex makes the blood analyzers and reagents hospital labs run every day.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from Q1 FY2027, mid-2026 · Every call on the record Checkpoint: Q1 FY2027 results test management's call that China demand bottoms out and recovers in H2 FY2027

The call

Sysmex's China business is shrinking hard while its Americas, EMEA, and rest-of-Asia units keep growing, and the reagent lock-in that built its lead is still intact everywhere else.

Sysmex sells machines and test strips that hospitals use to analyze blood samples. The company has locked in about half the world's blood-testing market by making machines and strips that work only together, like razors and blades, plus it has hard-to-get government approvals and long-term service contracts that keep customers tied to its products. Right now, profits dropped 40 percent because China told hospitals to buy less, and competitors like Beckman Coulter and Mindray are pushing cheaper alternatives, but outside China the business grew 6 to 13 percent, so the real question is whether China bounces back in the second half of 2027 and whether Mindray can convince hospitals in America and Europe to switch.

Why

AI pressure: None apparent. AI shows up inside Sysmex's own analyzers for cell classification, not yet as an outside tool replacing them. Could AI do the core job? Unlikely.

Bigger players: Shenzhen Mindray Bio-Medical Electronics. Mindray is pushing cheaper hematology analyzers upmarket into developed markets where Sysmex has run the table. Could a giant copy it? No, they are blocked.

What protects it. Reagents only work in Sysmex's own machines, so hospitals that bought the analyzer keep buying the consumables for years.

What would change this call

Sysmex China sales growth in H1 FY2027 results (due ~Nov 2026). Shows whether China demand stabilizes as management guided or keeps sliding.
Public U.S. or EU reference-lab RFP wins by Mindray or Beckman Coulter naming displaced Sysmex analyzers. Would show the reagent-instrument lock-in is breaking in developed markets.
Any new goodwill impairment disclosed in Sysmex's FY2027 annual results. Would signal recurring acquisition integration problems beyond FY2026's Partec writedown.

Key numbers

FY2026 operating profit fell 40.8% to Yen 51.8 billion (2026-05-14)
China sales down about 17.9% YoY in H1 FY2026 (2025-11-20)
FY2027 guidance calls for Yen 535.0 billion in sales (2026-05-14)

Named risks

China's 'principle of minimal necessity' policy suppressing test volumes into FY2027. Severity: high
Recurring goodwill impairments (e.g., FY2025 Sysmex Partec, FY2026 subsidiary) dragging reported profit. Severity: medium
Yen/dollar/yuan FX volatility affecting reported results given China-linked intercompany transactions. Severity: medium
Mindray and other rivals pushing upmarket with lower-cost analyzers into Sysmex's core tiers. Severity: medium
Integration execution risk from JEOL clinical chemistry acquisition closed April 2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Beckman Coulter (Danaher)	contesting	DxH 900 analyzer noted for AI-driven automation features, per market report Dec 2023
Abbott Laboratories	contesting	Runs a diversified diagnostics platform far larger than Sysmex overall, per 2026 industry reports
Siemens Healthineers	contesting	Named as key rival in clinical diagnostics/hematology market reports through 2026
Shenzhen Mindray Bio-Medical Electronics	contesting	Named as upmarket threat with lower TCO as of mid-2026, but no confirmed installed-base share loss reported

Questions people ask

Is Sysmex profitable in 2026?: Yes but profit fell sharply. For FY2026 (ended March 2026), Sysmex reported net sales of ¥500.0 billion (-1.7% YoY), operating profit of ¥51.8 billion (-40.8%), and profit attributable to owners of ¥35.4 billion (-33.9%), driven by China policy headwinds and goodwill impairment, per its May 14, 2026 results filing.
Who owns Sysmex Corporation?: Sysmex is an independent public company listed on the Tokyo Stock Exchange Prime Market (ticker 6869), with no parent company. As of April 2026, Hisashi Ietsugu serves as Chairman and Group CEO, and Iwane Matsui as President.
Could AI replace Sysmex's diagnostics business?: Unlikely soon. Sysmex's moat rests on FDA/EMA-cleared hardware, proprietary reagent chemistry, and a closed instrument-reagent ecosystem across 190+ export markets, which pure software cannot replicate. Sysmex itself is adding AI as a feature layer, launching 'Sysmex AI' digital solutions within FY2026 rather than being displaced by it.
Is Sysmex laying off employees?: No signs of layoffs; headcount has grown steadily, reaching 10,533 group employees as of March 31, 2025, up 4.89% year-on-year from 10,042 in March 2024, per Sysmex's own shareholder disclosures.
Who is Sysmex's biggest competitor?: Sysmex competes with Beckman Coulter (Danaher), Abbott Laboratories, and Siemens Healthineers in hematology and clinical diagnostics, while Shenzhen Mindray Bio-Medical Electronics is pushing upmarket with lower-cost analyzers, though no confirmed installed-base losses for Sysmex have been reported as of mid-2026.
Why did Sysmex's stock and profit struggle in 2026?: China's 'principle of minimal necessity' policy curbed diagnostic test volumes, cutting Sysmex's China sales roughly 17.9% year-on-year in H1 FY2026 (local currency), alongside distributor destocking and a goodwill impairment, pushing FY2026 operating profit down 40.8% to ¥51.8 billion.

Timeline

2026-05-27Sysmex America launches next-generation XR-Series hematology analyzer
2026-05-14FY2026 results: sales ¥500.0bn (-1.7%), operating profit ¥51.8bn (-40.8%)
2026-04-12Launches HISCL p-Tau217 Assay Kit for Alzheimer's biomarker research in Europe
2026-04-01Closes acquisition of JEOL's clinical chemistry testing business
2026-03-05Announces new Group Mid-Term Management Plan and equity buyback
2026-01Launches CN-9000 automated hemostasis solution for large North American labs
2025-11-20Reports H1 FY2026 China sales decline of ~17.9% YoY in local currency
2025-08FDA clears CN-6000 automated blood coagulation analyzer
2024-04Begins direct hemostasis sales in Europe and the U.S., ending distributor model
2023-10Acquires Roche's hematology business

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE